At the time of writing, Atyr Pharma Inc [ATYR] stock is trading at $3.81, up 6.72%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ATYR shares have gain 10.12% over the last week, with a monthly amount drifted -2.56%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 04, 2024, and set its price target to $17. On September 05, 2024, Jefferies initiated with a Buy rating and assigned a price target of $9 on the stock. Oppenheimer downgraded its rating to a Perform. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on October 12, 2021. Piper Sandler started tracking with a Overweight rating for this stock on September 21, 2021, and assigned it a price target of $19. In a note dated May 10, 2021, Laidlaw initiated an Buy rating and provided a target price of $18 on this stock.
For the past year, the stock price of Atyr Pharma Inc fluctuated between $1.42 and $4.22. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $3.81 at the most recent close of the market.
Analyzing the ATYR fundamentals
According to Atyr Pharma Inc [NASDAQ:ATYR], the company’s sales were 0.23M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at -5.64% with Operating Profit Margin at -289.59%, Pretax Profit Margin comes in at -271.55%, and Net Profit Margin reading is -271.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.79 and Total Capital is -0.88. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.63 points at the first support level, and at 3.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.93, and for the 2nd resistance point, it is at 4.05.
Ratios To Look Out For
It is important to note that Atyr Pharma Inc [NASDAQ:ATYR] has a current ratio of 5.41. In addition, the Quick Ratio stands at 5.41 and the Cash Ratio stands at 0.81. Considering the valuation of this stock, the price to sales ratio is 1390.50, the price to book ratio is 4.42.
Transactions by insiders
Recent insider trading involved Broadfoot Jill Marie, Chief Financial Officer, that happened on Feb 04 ’25 when 1254.0 shares were sold. General Counsel, DENYES NANCY completed a deal on Feb 04 ’25 to sell 899.0 shares. Meanwhile, Director SCHIMMEL PAUL bought 52300.0 shares on Jul 24 ’24.
